122 related articles for article (PubMed ID: 11982812)
1. Influence of target hemoglobin in dialysis patients on morbidity and mortality.
Collins AJ
Kidney Int Suppl; 2002 May; (80):44-8. PubMed ID: 11982812
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients.
Volkova N; Arab L
Am J Kidney Dis; 2006 Jan; 47(1):24-36. PubMed ID: 16377382
[TBL] [Abstract][Full Text] [Related]
3. Relationships between hemoglobin and hematocrit levels and hospitalization and survival rates in dialysis patients.
Brattich M
Nephrol Nurs J; 2003 Apr; 30(2):231-4. PubMed ID: 12737001
[TBL] [Abstract][Full Text] [Related]
4. Impact of hematocrit on morbidity and mortality.
Collins AJ; Ma JZ; Ebben J
Semin Nephrol; 2000 Jul; 20(4):345-9. PubMed ID: 10928336
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
6. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
7. Hematocrit level associated mortality in hemodialysis patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610-619, 1999.
Khan S; Pereira BJ
Semin Dial; 2000; 13(2):112-3. PubMed ID: 10795115
[No Abstract] [Full Text] [Related]
8. Trends in anemia treatment with erythropoietin usage and patient outcomes.
Collins AJ; Ma JZ; Xia A; Ebben J
Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S133-41. PubMed ID: 9892380
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Charytan C; Goldfarb-Rumyantzev A; Wang YF; Schwenk MH; Spinowitz BS
Am J Nephrol; 1998; 18(6):498-503. PubMed ID: 9845824
[TBL] [Abstract][Full Text] [Related]
10. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
11. The role of hematocrit in efficiency of dialysis.
Movilli E; Cancarini GC; Mombelloni S; Feller P; Ravelli M; Maiorca R
Blood Purif; 1990; 8(4):183-9. PubMed ID: 2085426
[TBL] [Abstract][Full Text] [Related]
12. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
[TBL] [Abstract][Full Text] [Related]
14. Morbidity and mortality in patients on dialysis: the impact of hemoglobin levels.
Brattich M
Nephrol Nurs J; 2006; 33(1):64-7, 90; quiz 68-9. PubMed ID: 16538929
[TBL] [Abstract][Full Text] [Related]
15. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease.
Strippoli GF; Manno C; Schena FP; Craig JC
Cochrane Database Syst Rev; 2003; (1):CD003967. PubMed ID: 12535495
[TBL] [Abstract][Full Text] [Related]
16. Challenging the validity of the EPO index.
Kaysen GA; Müller HG; Ding J; Chertow GM
Am J Kidney Dis; 2006 Jan; 47(1):166. PubMed ID: 16377397
[TBL] [Abstract][Full Text] [Related]
17. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
18. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Acharya VN; Sinha DK; Almeida AF; Pathare AV
J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
[TBL] [Abstract][Full Text] [Related]
19. [What are the aims and targets of renal anemia therapy?].
Eckardt KU
Dtsch Med Wochenschr; 2007 Sep; 132(36):1837-41. PubMed ID: 17726657
[No Abstract] [Full Text] [Related]
20. Comparative analysis between centrifuged hematocrit and "point-of-care" hemoglobin: impact on erythropoietin dosing.
Marooney M
ANNA J; 1998 Oct; 25(5):479-81. PubMed ID: 9887700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
